Stereotaxis

Stereotaxis R&D per Employee

The R&D Spending per Employee of Stereotaxis (STXS) as of Oct 12, 2026 is 71,625.95 USD. In the previous year, R&D Spending per Employee was 74,503.82 USD — a change of -3.86% (lower).

R&D per Employee

71,625.95USD

YoY

-3.86%

Last updated:

R&D Spending per Employee of Stereotaxis is 2025 71,625.95 USD. R&D Spending per Employee of Stereotaxis was 2024 74,503.82 USD. It decreases by -3.86% lower compared to the previous year.

The Stereotaxis R&D per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D per Employee
Date
R&D per Employee
Jan 1, 2018
62,743.41 USD
Jan 1, 2019
68,865.67 USD
Jan 1, 2020
62,113.85 USD
Jan 1, 2021
77,854.96 USD
Jan 1, 2022
80,595.42 USD
Jan 1, 2023
78,419.85 USD
Jan 1, 2024
74,503.82 USD
Jan 1, 2025
71,625.95 USD
The Stereotaxis R&D per Employee history
YEARR&D per EmployeeYoY
71,625.95USD-3.86%
74,503.82USD-4.99%
78,419.85USD-2.70%
80,595.42USD+3.52%
77,854.96USD+25.34%
62,113.85USD-9.80%
68,865.67USD+9.76%
62,743.41USD+72.65%
36,342.03USD-13.24%
41,890.15USD-12.24%
47,731.23USD+21.22%
39,376.57USD—
Access this data via the Eulerpool API

Stereotaxis Stock analysis

What does Stereotaxis do? Stereotaxis Inc, based in St. Louis, Missouri, is a company that specializes in the development and marketing of advanced instruments and services in magnetic resonance imaging (MRI) and electrophysiology (EP). The company was founded in 1990 and its mission is to improve the accuracy, safety, and efficiency of MRI and EP procedures. The business model of Stereotaxis is based on providing a comprehensive range of systems, instruments, and services to support hospitals and clinics in performing MRI and EP procedures. The company focuses on developing innovative technologies and solutions to improve clinical outcomes and provide the best possible treatment for patients. The company has four main divisions: magnetic resonance imaging (MRI), electrophysiology (EP), cardiovascular diagnostics, and cardiology. In the MRI division, the company offers a variety of instruments and systems specifically designed for MRI procedures. This includes magnetic field control systems, imaging systems, sample collection and analysis instruments, and controls to make MRI procedures more efficient. In the electrophysiology division, Stereotaxis offers instruments and systems that facilitate the navigation and control of medical devices during EP procedures. This includes magnetic field controls and other technologies to improve the accuracy of catheter placement and increase safety during procedures. Stereotaxis's cardiovascular diagnostics division offers various services and technologies that facilitate the performance of cardiology procedures. This includes a comprehensive diagnostic platform that allows for the analysis of heart images. The cardiology division of Stereotaxis offers a comprehensive range of solutions to improve the performance of cardiology procedures in cardiology clinics and hospitals. This includes a range of technologies to improve the diagnosis and treatment of heart diseases. In recent years, Stereotaxis has developed a variety of innovative solutions and technologies to improve the performance of MRI and EP procedures. One example is Robotic Magnetic Navigation, a technology developed by the company to improve the accuracy and safety of EP procedures. This technology allows doctors to improve the navigation and control of catheters during procedures, thereby providing patients with increased treatment safety. Another example is Stereotaxis's Odyssey platform, a solution developed to enable real-time connectivity between various medical devices. This allows doctors to access a variety of information during procedures and make the performance of procedures more efficient. Overall, Stereotaxis has an impressive track record in the development and marketing of advanced solutions and technologies in the MRI and EP industry in recent years. With its innovative technology and comprehensive range of instruments and services, the company is well positioned to continue playing a key role in healthcare in the future. Stereotaxis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stereotaxis stock

R&D Spending per Employee of Stereotaxis is 71,625.95 USD in 2025.

R&D Spending per Employee of Stereotaxis changed from 74,503.82 USD to 71,625.95 USD, representing a -3.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of R&D Spending per Employee Stereotaxis since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Stereotaxis historically and in real time.

Access this data via the Eulerpool API

Workforce — Stereotaxis

All Key Metrics — Stereotaxis